Avamys (fluticason furoat)
Fluticasone has been on the market for many years as fluticasone-propionate. A new derivate of fluticasone, fluticasone-furoate, is marketed as Avamys.
There hasn’t been made any comparative studies between fluticason-furoate nasal spray and other nasal corticosteroids.
Fluticasone-furoate has in a study of children and adults shown improved symptoms in allergic rhinitis and life quality to higher extent than placebo. The incipient effect started 8 hours after administration.
Fluticasone-furoate induce side effects at placebo level except epitaxis, that can be found in approximately 20 % of the treated against 8 % in the placebo group.
Fluticasone-furoate is approximately at the same price level as other nasal corticosteroids.
Fluticasone-furoate was marketed the 24th of March 2008.